Boston Scientific is a Buy with a $109 target and 14% upside from strong demand, Q3 beats, raised FY25 guidance, and growth ...
Authorities have uncovered massive fraud in Minnesota, with billions of taxpayer dollars potentially lost. First Assistant ...
A coroner has found that failure to drain a litre of alcoholic betadine from a patient prior to his discharge from a major ...
Two treatments that can be traced back to the 1800s in their earliest forms have been updated and improved, as a growing ...
Medical Device Network on MSN
What 2025 reveals about medtech’s next leap in 2026
No one can predict what the medical device industry will look like in 2026. Still, the events of 2025 provide meaningful ...
When lungs fail to maintain vital oxygen and carbon dioxide levels, respiratory failure occurs, posing a serious threat. This condition, categorized as Type I (low oxygen) or Type II (high carbon ...
Affluent Medical recently announced agreements to acquire Caranx Medical and Artedrone to form a new medtech company called ...
Writer-director James Cameron and his department heads talk with IndieWire about obliterating boundaries between ...
Three start-ups are aiming to create gene-edited babies. Columnist Michael Le Page has no doubt that editing our offspring ...
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the ...
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") , a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback